Galapagos NV (GLPG)

187.79
2.20 1.20
NASDAQ : Health Technology
Prev Close 185.56
Open 185.44
Day Low/High 184.68 / 186.29
52 Wk Low/High 112.00 / 274.03
Volume 18.50K
Avg Volume 96.60K
Exchange NASDAQ
Shares Outstanding 65.25M
Market Cap 13.29B
EPS 2.90
Div & Yield N.A. (N.A)

Latest News

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

Inverted Yield Curve Has Lost a Lot of Its Predictive Power

The market has given up some of its early gains, but the major indices are all still in the black. Homebuilders have given up their 1% rally early today and now are flat. The Atlanta Fed's GDPNow has the economy growing 1.7% now from the last readin...

Before the Open

Less than a hour to go before the market open as we await the last trading day of the first quarter. Pre-market futures are still pointing to a up opening. Gilead Sciences is up some 2% this morning after developmental partner Galapagos announced so...

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Seeing the Same Old Patterns Ahead of Fed News

Seeing the Same Old Patterns Ahead of Fed News

Buyers expect a dovish Fed and are still trying to put money to work.

Don’t Give Up On Gilead Sciences

Don’t Give Up On Gilead Sciences

The biotech juggernaut still has a lot going for it, especially at these levels.

3 Biotech Stocks to Buy Right Now

3 Biotech Stocks to Buy Right Now

With low multiples and solid yields, these names look good for the long term.

What to Watch When 3 Big Biotechs Report

What to Watch When 3 Big Biotechs Report

Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.

3 Biotech Stocks to Buy into 2016

3 Biotech Stocks to Buy into 2016

GILD, CELG and ABBV will lead the biotech resurgence.

Apple and Gilead: Cash Kings to Own

Apple and Gilead: Cash Kings to Own

These large-cap stocks will do well in any market.

Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA

Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA

Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%.